Status:
TERMINATED
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Tumors Metastatic to Brain
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to...
Detailed Description
PRIMARY OBJECTIVES: I. To correlate pre-treatment measures of biophysical parameters in metastases-obtained using advanced, quantitative MRI techniques in patients receiving standard-of-care (SOC) th...
Eligibility Criteria
Inclusion
- Patients must sign an Institutional Review Board (IRB)-approved informed consent document
- Patients must have been diagnosed with one of the following:
- Primary brain tumor (glioma, GBM etc); or
- Up to 10 brain metastases
- Patients must have been diagnosed with 1-4 brain metastases
- At least one of the brain metastases must measure 5 mm (or more) in short axis diameter in the axial plane
- Patients must be scheduled to undergo standard brain cancer interventions:
- Chemotherapy or targeted antiangiogenic therapy, in the case of primary brain tumor; or
- Stereotaxic radiotherapy (SRS) or whole brain radiotherapy (WBRT), in the case of brain metastases.
- Patients must be scheduled to receive a 3-Tesla (3T) MRI exam as part of their standard of care (this exam will be modified to also include pulse sequences with are for research only)
Exclusion
- Patients who have received previous treatment (chemotherapy or radiotherapy) for any brain tumor (primary or metastatic).
- Patients who are scheduled to receive a 1.5T MRI exam
- Patients incapable of giving informed written consent, due to mental disability, altered mental status, confusion, cognitive impairment, or psychiatric disorders.
- Patients scoring 14.5 or lower on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire will not be allowed on the study
Key Trial Info
Start Date :
April 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02269111
Start Date
April 1 2015
End Date
May 1 2018
Last Update
May 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232